Group 1 - The company, Nanjing Novogene Biotechnology Co., Ltd., has announced that its subsidiary has obtained medical device registration certificates for multiple diagnostic reagent products related to neurological diseases [1][4] - Alzheimer's Disease (AD) is highlighted as a significant public health issue due to the aging global population, leading to memory impairment and cognitive decline [1][2] - The company has developed several blood biomarkers for AD, making it the largest manufacturer in China for AD core biomarker detection through blood samples [2][3] Group 2 - Parkinson's Disease (PD) is identified as the second most common neurodegenerative disease, characterized by the loss of dopaminergic neurons and the aggregation of α-synuclein [3] - The oligomerization rate of α-synuclein is noted as an effective predictor for distinguishing PD patients from healthy controls, and it serves as a specific marker for differentiating between AD and other α-synucleinopathies [3] - The company aims to enhance its product offerings in the central nervous system disease area, focusing on innovative detection and diagnostic products for PD and brain injuries [2][3]